![Canadian Manufacturing](https://www.canadianmanufacturing.com/wp-content/uploads/2024/09/CMO-Logo-2024sm.png)
Aurora Cannabis receives expanded cultivation and research licenses for German facility
by CM Staff
Under the new license, Aurora Cannabis may also cultivate an approved additional product, and plans to expand their offerings to the rapidly growing German patient base.
EDMONTON — Aurora Cannabis Inc., a Canadian-based global medical cannabis company, has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany’s new Medical Cannabis Act (MedCanG). Aurora’s license grants the company continued domestic cultivation, which has been underway for two years now. Under the new license, Aurora may also cultivate an approved additional product, and plans to expand their offerings to the rapidly growing German patient base. Aurora will also receive a dedicated R&D license, allowing for the trial of up to seven additional novel cultivars at the company’s local EU GMP facility in Leuna, Germany.
“We thank the German government for its continued investment in the growth of medical cannabis, made possible by decriminalization, which will improve access to medical cannabis for patients all across Germany,” says Michael Simon, President, Aurora Europe. “Being one of the few companies to receive enhanced licenses is a testament to Aurora’s established leadership in the region and unparalleled commitment to making available the highest quality cannabis. We now have the framework to extend our portfolio, invest in domestic research and leverage Aurora’s global cultivation expertise locally.”
Aurora says they are committed to the growth, acceptance and broader access to medical cannabis globally. The company’s leadership in Europe is a result of ongoing collaboration with government, regulators and industry. Since 2021, Aurora’s medical cannabis production facility, located in Leuna, Saxony-Anhalt, has been cultivating approximately 1,000 kg (about 2204 lb) of medical cannabis flower annually as part of a tender agreement with BfArM. The company has demonstrated a commitment to product efficacy that has led to the granting of additional licenses. These additional licenses are a result of the company’s continued focus on quality and compliance.
The company says they support Germany’s investment in meaningful regulatory reform, and anticipates it will have broader effect on the expanding acceptance of medical cannabis and future modern frameworks across Europe. Aurora’s domestic and global background in developing products, positions the company to fulfill growing patient demand.
- Hyundai Motor Group and Bell Canada expand partnership, enhancing in-car services
- $500M settlement reached with George Weston Ltd. and Loblaw Companies Ltd. in bread price-fixing scandal